Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 16.2% in October

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 45,100 shares, a growth of 16.2% from the September 30th total of 38,800 shares. Based on an average daily trading volume, of 182,400 shares, the days-to-cover ratio is presently 0.2 days.

Astellas Pharma Stock Performance

Shares of ALPMY stock traded up $0.37 during trading hours on Tuesday, reaching $11.64. 120,863 shares of the company traded hands, compared to its average volume of 236,906. The firm has a 50-day moving average price of $11.97 and a 200 day moving average price of $10.80. The company has a market cap of $21.06 billion, a P/E ratio of 166.29 and a beta of 0.37. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.90 and a quick ratio of 0.72. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.24 earnings per share for the quarter. The business had revenue of $3.03 billion for the quarter. Astellas Pharma had a net margin of 1.17% and a return on equity of 7.79%. As a group, sell-side analysts predict that Astellas Pharma will post 0.54 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.